该研究旨在评估接受免疫检查点抑制剂的晚期食管鳞状细胞癌（ESCC）治疗前炎症生物标志物与临床结果之间的联系。2019年至2022年间，我们分析了354名被诊断患有转移性食管鳞状细胞癌并接受免疫治疗的个体。该研究旨在评估特定炎症生物标志物（中性粒细胞/淋巴细胞比值 (NLR)、C 反应蛋白与白蛋白比值 (CRP/ALB) 和格拉斯哥预后评分 (GPS)、环氧化酶-2 (COX-2) 抑制剂或该研究利用 Kaplan-Meier 和 Cox 回归模型以及倾向评分匹配进行分析。研究结果显示，治疗前 NLR 升高（11.0 个月与 14.6 个月，p = 0.021）。 ）和 CRP/ALB（11.4 个月与 14.6 个月，p = 0.022）水平与较差的总生存期 (OS) 结果显着相关，而类固醇的使用并未显示出 OS 的显着差异（15.5 个月与 15.4 个月，p同样，在使用 COX-2 抑制剂治疗的患者和未使用 COX-2 抑制剂治疗的患者之间，未观察到 OS 存在显着差异（13.8 个月与 11.0 个月，p= 0.054）。治疗前 NLR 和 CRP/ALB 水平较低。与晚期 ESCC 免疫治疗的更好疗效和 OS 相关。该研究并未发现食管癌患者的 OS 与类固醇或 COX-2 抑制剂的使用之间存在显着关系。© 2024。作者获得 Federación de Sociedades Españolas de Oncología (FESEO) 的独家许可。

The research aimed to evaluate the connection between pre-treatment inflammatory biomarkers and clinical results in advanced esophageal squamous cell carcinoma (ESCC) receiving immune checkpoint inhibitors.Between 2019 and 2022, we analyzed 354 individuals diagnosed with metastatic ESCC who underwent immunotherapy. The study sought to evaluate the impact of specific inflammatory biomarkers (Neutrophil/Lymphocyte Ratio (NLR), C-reactive protein to albumin ratio (CRP/ALB) and Glasgow Prognostic Score (GPS), Cyclooxygenase-2 (COX-2) inhibitors or steroids usage on the effectiveness and survival outcomes of immunotherapy in advanced ESCC. The research utilized Kaplan‒Meier and Cox regression models alongside propensity score matching for analysis.The findings revealed that elevated pre-treatment NLR (11.0 vs. 14.6 months, p = 0.021) and CRP/ALB (11.4 vs. 14.6 months, p = 0.022) levels were significantly associated with poorer overall survival (OS) outcomes, while the use of steroids did not show a significant difference in OS (15.5 vs. 15.4 months, p = 0.685) between groups. Similarly, no notable disparity in OS was observed between patients treated withCOX-2 inhibitors and those who were not (13.8 vs. 11.0 months, p = 0.054).Lower levels of NLR and CRP/ALB prior to treatment were linked to better effectiveness and OS in immunotherapy for advanced ESCC. The study did not identify a significant relationship between OS in patients with esophageal cancer and the use of either steroids or COX-2 inhibitors.© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).